The compliance of doctors with viral hepatitis B screening and antiviral prophylaxis in cancer patients receiving cytotoxic chemotherapy using a hospital-based screening reminder system (Q35057889)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	The compliance of doctors with viral hepatitis B screening and antiviral prophylaxis in cancer patients receiving cytotoxic chemotherapy using a hospital-based screening reminder system	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

The compliance of doctors with viral hepatitis B screening and antiviral prophylaxis in cancer patients receiving cytotoxic chemotherapy using a hospital-based screening reminder system (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

0 references

1 reference

based on heuristic

inferred from title

viral hepatitis

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25658926%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

Wei-Chih Sun

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25658926%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Ping-I Hsu

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25658926%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Hsien-Chung Yu

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25658926%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Feng-Woei Tsay

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25658926%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Huay-Min Wang

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25658926%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Tzung-Jiun Tsai

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25658926%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Wen-Chi Chen

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25658926%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Kwok-Hung Lai

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25658926%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Jin-Shiung Cheng

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25658926%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

language of work or name

0 references

publication date

6 February 2015

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25658926%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25658926%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25658926%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

e0116978

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25658926%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

copyright license

Creative Commons Attribution 4.0 International

6 February 2015

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319781

8 July 2018

Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319781

8 July 2018

Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319781

8 July 2018

Testing for hepatitis B infection in prospective chemotherapy patients: a retrospective study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319781

8 July 2018

Low rates of hepatitis B virus screening at the onset of chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319781

8 July 2018

Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319781

8 July 2018

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319781

8 July 2018

Current hepatitis B screening practices and clinical experience of reactivation in patients undergoing chemotherapy for solid tumors: a nationwide survey of medical oncologists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319781

8 July 2018

Updated longitudinal data on acute exacerbation of chronic hepatitis B in patients with breast cancer receiving anthracycline-based adjuvant chemotherapy: therapeutic vs. pre-emptive use of lamivudine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319781

8 July 2018

Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319781

8 July 2018

Screening for hepatitis B surface antigen before chemotherapy: current practice and opportunities for improvement

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319781

8 July 2018

Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319781

8 July 2018

Chronic hepatitis B: update 2009

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319781

8 July 2018

Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319781

8 July 2018

Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319781

8 July 2018

Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319781

8 July 2018

Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319781

8 July 2018

Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319781

8 July 2018

Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319781

8 July 2018

A phase II study of gemcitabine plus oral etoposide in the treatment of patients with advanced nonsmall cell lung carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319781

8 July 2018

Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319781

8 July 2018

Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319781

8 July 2018

Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319781

8 July 2018

Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319781

8 July 2018

Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319781

8 July 2018

Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319781

8 July 2018

Fatal reactivation of hepatitis B with temozolomide

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0116978

21 January 2018

Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0116978

21 January 2018

A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0116978

21 January 2018

Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0116978

21 January 2018

Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0116978

21 January 2018

Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0116978

21 January 2018

Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0116978

21 January 2018

Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0116978

21 January 2018

Oncologists and hepatitis B: a survey to determine current level of awareness and practice of antiviral prophylaxis to prevent reactivation

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0116978

21 January 2018

Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0116978

21 January 2018

Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0116978

21 January 2018

Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0116978

21 January 2018

Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0116978

21 January 2018

A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy?

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0116978

21 January 2018

Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0116978

21 January 2018

Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0116978

21 January 2018

Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders

1 reference

https://pubmed.ncbi.nlm.nih.gov/25658926

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Screening for hepatitis B in chemotherapy patients: survey of current oncology practices

1 reference

https://pubmed.ncbi.nlm.nih.gov/25658926

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preventing chemotherapy-induced hepatitis B reactivation in breast cancer patients: a prospective comparison of prophylactic versus deferred preemptive lamivudine

1 reference

https://pubmed.ncbi.nlm.nih.gov/25658926

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0116978

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25658926%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

2015PLoSO..1016978S

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25658926%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25658926%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35057889&oldid=1858507396"